Q&A – June 20, 2025

by Steven Grossman | Jun 28, 2025 | Uncategorized | 0 comments

Permission is granted to reprint or recirculate this column, as long as attribution is made to FDA Matters and the author.

Dear FDA Matters subscribers–

There was one FDA Matters column this week. Alice, Humpty Dumpty and the New Administration, in which I explored the meaning of radical transparency, gold-standard science, and ultra-processed foods.

I also posted a comment (here) on the new National Priorities Voucher (NPV) initiative at FDA. When we have more details, I will probably produce an entire column about it.

Looking for Questions from Readers. When I wrote “Friday Update” for the Alliance for a Stronger FDA (about six hundred columns over 15 years), some of my best-read columns were in response to questions I received from Alliance members.

In that same spirit of give and take, I welcome questions from FDA Matters’ subscribers (including members of the media). Please send your toughest questions about any aspect of FDA’s mission, responsibilities, programs, and policies to: sgrossman@fdamatters.com.

I will try to respond in a way that makes all of us a little smarter about the agency. As a “for example,” I was asked yesterday whether I thought all the efforts to shorten the approval process risked a thalidomide-type situation with no place for a Frances Kelsey to express concerns. I have an intriguing answer…which I will share in the first FDA Matters Q&A column.

HPS Group, my consulting firm, is accepting new clients and projects. While FDA Matters will always be a work in progress (new columns and new features coming), I can now turn my attention to the re-launch of my consulting firm, HPS Group.

I am a policy analyst, problem solver, and writer with deep experience in FDA and NIH issues and an insightful perspective on advocacy in DC.

At various points, I have done coalition development, strategic plans, built and implemented communications and public affairs programs, and written op-eds and white papers. I have worked in and for associations, in the Senate, at HHS, and at a large public relations/public affairs company. I have been an independent consultant for many years, including while I was at the Alliance.

You may retain HPS Group to provide ongoing counsel or ask for assistance with specific projects from reviewing documents to long-term planning. If it’s challenging, I am up for it…even if it is only a small, short-term assignment helping you think through a problem.

Let’s chat…if I can’t offer you what you need, I have worked with a vast number of people I can recommend.

You can reach me at sgrossman@hpsgroup.com or at 301-257-9660.

Have a great weekend,

Steven

FDA Matters provides short-form analysis of FDA policy and regulatory issues. We know you are busy, so we publish 1 to 2 columns per week, each a 3-5 minute read.

FDA Matters does not report the news….we provide analysis of what’s behind the news.

FDA Matters advocates for a more effective, efficient, and fair FDA.

FDA Matters has been featured in:

Steven Grossman

Steven A. Grossman, JD, is the founder and author of FDA Matters. Read more about Steven here.